A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 85-89

  Gatcliffe, Troy A ^a   Tewari, Krishnansu S ^a   Shah, Amy ^b   Brewster, Wendy R ^a   Burger, Robert A ^a   Kuo, Jeffrey V ^a   Monk, Bradley J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cervical cancer; Cisplatin; Radiation therapy; Topotecan

Indexed keywords

CISPLATIN; TOPOTECAN;

ADENOCARCINOMA; ADENOSQUAMOUS CARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUOUS INFUSION; DEEP VEIN THROMBOSIS; EXTERNAL BEAM RADIOTHERAPY; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; HYPERKALEMIA; HYPONATREMIA; LABORATORY TEST; LEUKOPENIA; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PATIENT MONITORING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK ASSESSMENT; SMALL INTESTINE OBSTRUCTION; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRACHYTHERAPY; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; SURVIVAL RATE; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 57649221958     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.09.029     Document Type: Article

References (21)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 2 (2008) 71-96 [Mar-Apr]
2. Garcia M., Jemal A., Ward E., Center M.M., Hao Y., Siegel R., et al. Global cancer facts & figures 2007 (2007), American Cancer Society, Atlanta, GA
3. Ries L.A.G., Young J.L., Keel G.E., et al. SEER survival monograph: cancer survival among adults: U.S. SEER Program, 1988-2001, patient and tumor characteristics (2007), National Cancer Institute, SEER Program, Bethesda, MD
4. The National Cancer Institute Clinical Announcement on Cervical Cancer. 1999 [cited; Available from: http://cancer.gov/newscenter/cervicalcancer.
5. Rose P.G. Chemoradiotherapy: the new standard care for invasive cervical cancer. Drugs 60 6 (2000) 1239-1244 [Dec]
6. Keys H.M., Bundy B.N., Stehman F.B., Muderspach L.I., Chafe W.E., Suggs III C.L., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N. Engl. J. Med. 340 15 (1999) 1154-1161 [Apr 15]
7. Morris M., Eifel P.J., Lu J., Grigsby P.W., Levenback C., Stevens R.E., et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N. Engl. J. Med. 340 15 (1999) 1137-1143 [Apr 15]
8. Rose P.G., Bundy B.N., Watkins E.B., Thigpen J.T., Deppe G., Maiman M.A., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N. Engl. J. Med. 340 15 (1999) 1144-1153 [Apr 15]
9. Whitney C.W., Sause W., Bundy B.N., Malfetano J.H., Hannigan E.V., Fowler Jr. W.C., et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J. Clin. Oncol. 17 5 (1999) 1339-1348 [May]
10. Peters III W.A., Liu P.Y., Barrett II R.J., Stock R.J., Monk B.J., Berek J.S., et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin Oncol. 18 8 (2000) 1606-1613 [Apr]
11. Monk B.J., Tewari K.S., and Koh W.J. Multimodality therapy for locally advanced cervical carcinoma: state of the art and future directions. J. Clin. Oncol. 25 20 (2007) 2952-2965 [Jul 10]
12. Fiorica J.V. The role of topotecan in the treatment of advanced cervical cancer. Gynecol. Oncol. 90 3 Pt 2 (2003) S16-S21 [Sep]
13. Fiorica J., Holloway R., Ndubisi B., Orr J., Grendys E., Boothby R., et al. Phase II trial of topotecan and cisplatin in persistent or recurrent squamous and nonsquamous carcinomas of the cervix. Gynecol. Oncol. 85 1 (2002) 89-94 [Apr]
14. Long III H.J., Bundy B.N., Grendys Jr. E.C., Benda J.A., McMeekin D.S., Sorosky J., et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23 21 (2005) 4626-4633 [Jul 20]
15. Monk B.J., Huang H.Q., Cella D., and Long III H.J.. Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study. J. Clin. Oncol. 23 21 (2005) 4617-4625 [Jul 20]
16. Kim J.H., Kim S.H., Kolozsvary A., and Khil M.S.. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys. 22 3 (1992) 515-518
17. Bell M.C., Davidson S.A., Mathis J.M., and Amphil F.. Topotecan concomitant with primary brachytherapy radiation in patients with cervical carcinoma: a phase I trial. Gynecol. Oncol. 80 2 (2001) 128-131 [Feb]
18. Dunton C.J., King S.A., Neufeld J., Tolosa J., Perez G., Avila A., et al. Phase I study of topotecan and radiation therapy in advanced cervical cancer. Gynecol. Oncol. 85 1 (2002) 185-187 [Apr]
19. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 3 (2000) 205-216 [Feb 2]
20. Monk B.J., Tian C., Rose P.G., and Lanciano R. Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials. Gynecol. Oncol. 105 2 (2007) 427-433 [May]
21. Thomas G., Ali S., Hoebers F.J., Darcy K.M., Rodgers W.H., Patel M., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol. Oncol. 108 2 (2008) 317-325 [Feb]